Clinical Trial Update: ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating ANGIOCOMB, an antiangiogenic therapy, in pediatric patients with diffuse brainstem and thalamic tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brainstem Glioma
• Thalamic Tumor

Drugs mentioned

• ANGIOCOMB

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: Brainstem Glioma | Phase 2 | Status: COMPLETED